ByteDance spins off AI drug unit that raises $290M

8 sources
  • ByteDance spun off its AI drug discovery unit Anew Labs, which raised $290 million at a $1.5 billion valuation, according to Reuters.
  • The round was led by HSG (formerly Sequoia China), IDG Capital, and Hillhouse Investment, with ByteDance retaining a 56% stake.
  • Anew Labs has four drug candidates and operations in Shanghai, Singapore, and San Jose, with about 50 core staff transferring from ByteDance.
Sources (8)
  1. 1 ByteDance completes $290 million fundraising for AI drug unit after its spin-off, sources say www.reuters.com
  2. 2 ByteDance's AI drug unit Anew Labs raises $290M at $1.5B valuation, Reuters reports thenextweb.com
  3. 3 ByteDance completes $369 million fund raising for AI drug unit after its spin-off, sources say www.straitstimes.com
  4. 4 ByteDance's AI Drug Unit Raises $290 Million After Spin-Off finimize.com
  5. 5 ByteDance’s AI drugmaking spin-off raises $290 million at $1.5 billion valuation, sources say www.moneycontrol.com
  6. 6 ByteDance's Anew Labs raises $290M for AI drug discovery at $1.5B valuation app.dealroom.co
  7. 7 ByteDance completes $290 million fundraising for AI drug unit after its spin-off, sources say www.tradingview.com
  8. 8 ByteDance completes $290 million fundraising for AI drug unit after its spin-off www.emirates247.com